Newlimit, the longevity biotech co-founded by Coinbase CEO Brian Armstrong, has raised $435 million in a Series C round led by Founders Fund, roughly tripling the company’s valuation to about $3.1 billion.
Key Takeaways:
Newlimit raised a $435 million Series C led by Founders Fund, announced June 2.The round lifted the biotech’s valuation to about $3.1 billion, roughly triple its prior mark.Newlimit plans to bring its first cell-aging reprogramming medicine into human trials next year.The financing drew a roster of high-profile backers, including new investors like Thrive Capital, Greenoaks, and Quiet Capital. Returning supporters included Kleiner Perkins, Abstract, and Valor Equity Partners, each of whom added to their existing stakes.
Founded in 2021 by Armstrong, former GV partner and bioengineer Blake Byers, and stem cell biologist Mark Kimmel, Newlimit is built on a single thesis, i.e. aging is “plastic,” or reversible, at the cellular level. The company develops medicines designed to restore youthful function to old cells through epigenetic reprogramming, a technique that aims to reset how genes are expressed without altering the underlying DNA.
From a Side Project to a $3 Billion BetNewlimit has grown quickly and the numbers spell that quite clearly. The startup raised $130 million as recently as last year, meaning the new round more than triples its valuation in roughly twelve months. The company has said the accelerated timeline was driven by a prototype medicine breakthrough that reverses cell age in old human liver cells, giving the team confidence to push toward the clinic.
Moreover, epigenetic reprogramming, the science underpinning Newlimit, has become one of the most closely watched and heavily funded areas of biotechnology. The approach builds on Nobel-winning research showing that mature cells can be coaxed back toward a younger state, and a wave of startups has raced to turn that insight into therapies. Newlimit’s latest raise places it among the best-capitalized names in the field.
Armstrong’s Expanding FootprintThe next test is the clinic and Newlimit’s move into human trials next year will be the first real-world read on whether its laboratory results translate into safe, effective medicines.
